articleTop 1% cited

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Cancer · 2003 · Vol. 97(12) · pp. 2972–2977

Johanna C. Bendell✉(Dana-Farber Cancer Institute)Susan M. Domchek(University of Pennsylvania)Harold J. Burstein(Harvard University)Lyndsay N. Harris(Harvard University)Jerry Younger(Massachusetts General Hospital)Irene Kuter(Massachusetts General Hospital)Craig A. Bunnell(Harvard University)Montserrat Rué(Dana-Farber Cancer Institute)Rebecca Gelman(Harvard University)Eric P. Winer(Dana-Farber Cancer Institute)

View via DOI Publisher page

Abstract

Metastatic breast carcinoma to the CNS is common among patients receiving trastuzumab-based therapy, including patients responding to therapy outside the CNS. This may be due either to predilection for the CNS by HER-2-positive tumor cells and/or poor penetration of the CNS by trastuzumab or to improved visceral disease control leading to a longer life and onset of late tumor spread to the CNS. Efforts to characterize other risk factors for development of CNS disease, optimal screening algorithms, and new treatment strategies may be warranted.

Brain Metastases and Treatment HER2/EGFR in Cancer Research Cancer Treatment and PharmacologyMedicineTrastuzumabMetastatic breast cancerBreast cancerOncologyInternal medicineBrain metastasisBreast carcinomaMetastasisChemotherapy

MeSH terms

TrastuzumabAntibodies, MonoclonalAntineoplastic AgentsBrain NeoplasmsBreast NeoplasmsFemaleHumansMeningeal NeoplasmsMiddle AgedRetrospective StudiesRisk FactorsSurvival AnalysisErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-2Antibodies, Monoclonal, Humanized

Citations

1,317

FWCI

23.03

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Metastatic Behavior of Breast Cancer Subtypes